Impaired mitophagosome–lysosome fusion mediates olanzapine‐induced aging
Aging Cell · 2023-11 · 22 (11)
DOI: 10.1111/acel.14003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Cell, online erschienen am 13.10.2023. Verfasst von Xi Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Medical, Indigenous and Health Sciences, University of Wollongong, Wollongong, New South Wales, Australia. Hauptthemen laut MEDLINE: Antipsychotic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Health and Medical Research Council.
Abstract (Originalsprache)
The lifespan of schizophrenia patients is significantly shorter than the general population. Olanzapine is one of the most commonly used antipsychotic drugs (APDs) for treating patients with psychosis, including schizophrenia and bipolar disorder. Despite their effectiveness in treating positive and negative symptoms, prolonged exposure to APDs may lead to accelerated aging and cognitive decline, among other side effects. Here we report that dysfunctional mitophagy is a fundamental mechanism underlying accelerated aging induced by olanzapine, using in vitro and in vivo ( Caenorhabditis elegans ) models. We showed that the aberrant mitophagy caused by olanzapine was via blocking mitophagosome–lysosome fusion. Furthermore, olanzapine can induce mitochondrial damage and hyperfragmentation of the mitochondrial network. The mitophagosome–lysosome fusion in olanzapine‐induced aging models can be restored by a mitophagy inducer, urolithin A, which alleviates defective mitophagy, mitochondrial damage, and fragmentation of the mitochondrial network. Moreover, the mitophagy inducer ameliorated behavioral changes induced by olanzapine, including shortened lifespan, and impaired health span, learning, and memory. These data indicate that olanzapine impairs mitophagy, leading to the shortened lifespan, impaired health span, and cognitive deficits. Furthermore, this study suggests the potential application of mitophagy inducers as therapeutic strategies to reverse APD‐induced adverse effects associated with accelerated aging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medical, Indigenous and Health Sciences, University of Wollongong, Wollongong, New South Wales, Australia.
- Jiangsu Key Laboratory of Immunity and Metabolism, Jiangsu International Laboratory of Immunity and Metabolism, Department of Pathogen Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu, China.
ORCID-Profile: Xu-Feng Huang
Förderung
- NIH HHS
- National Health and Medical Research Council
Zitieren
APA
Chen, X., Wang, Z., Zheng, P., Dongol, A., Xie, Y., Ge, X., Zheng, M., Dang, X., Seyhan, Z. B., Nagaratnam, N., Yu, Y., & Huang, X. F. (2023). Impaired mitophagosome–lysosome fusion mediates olanzapine‐induced aging. Aging Cell, 22(11). https://doi.org/10.1111/acel.14003
Vancouver
Chen X, Wang Z, Zheng P, Dongol A, Xie Y, Ge X, et al. Impaired mitophagosome–lysosome fusion mediates olanzapine‐induced aging. Aging Cell. 2023;22(11). doi:10.1111/acel.14003
BibTeX
@article{Chen2023,
author = {Chen, Xi and Wang, Zhizhen and Zheng, Peng and Dongol, Anjila and Xie, Yuanyi and Ge, Xing and Zheng, Mingxuan and Dang, Xuemei and Seyhan, Zehra Boz and Nagaratnam, Nathan and Yu, Yinghua and Huang, Xu-Feng},
title = {Impaired mitophagosome–lysosome fusion mediates olanzapine‐induced aging},
journal = {Aging Cell},
year = {2023},
volume = {22},
number = {11},
doi = {10.1111/acel.14003}
}
EUVIMED